Quarterly ResultAug 6, 2026, 04:22 PM
Zentalis Q2 Net Loss $(42.3)M; Cash $174.6M; DENALI Readout 1H 2027
AI Summary
Zentalis Pharmaceuticals reported a net loss of $(42.3) million for Q2 2026, with cash, cash equivalents, and marketable securities totaling $174.6 million as of June 30, 2026, providing a cash runway into late 2027. The company announced significant progress for its WEE1 inhibitor, azenosertib, including completing enrollment for DENALI Part 2a and 2b, with a topline readout expected in 1H 2027. Regulatory discussions with the FDA support an accelerated approval strategy for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer.
Key Highlights
- Net loss for Q2 2026 was $(42.3) million, compared to $(26.9) million in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $174.6 million as of June 30, 2026.
- Existing cash provides a runway into late 2027.
- Research and development expenses increased to $35.2 million in Q2 2026 from $27.6 million in Q2 2025.
- General and administrative expenses were $9.2 million in Q2 2026, up from $8.4 million in Q2 2025.
- DENALI Part 2 topline readout for azenosertib is expected in 1H 2027.
- Enrollment completed for DENALI Parts 2a and 2b.
- First patient dosed in the ASPENOVA Phase 3 confirmatory trial in May 2026.
Price Impact
More from ZNTL